Results 101 to 110 of about 2,435 (141)

Quality-by-Design-Driven RP-HPLC Method Development and Validation for Impurity Analysis of Elexacaftor, a Cystic Fibrosis Drug, with LC-MS/MS-Based Degradant Identification. [PDF]

ACS Omega
Raghupathi JK, Vemuri DK, Ali SM, Polisetti VK, Gundla R, Kowtharapu LP, Ramachandran D, Katari NK.   +7 more
europepmc   +1 more source

Impact of Elexacaftor-Tezacaftor-Ivacaftor on Quality of Life in Children With Cystic Fibrosis. [PDF]

Pediatr Pulmonol
Kümmerli S, Elviro CF, Regamey N, Mornand A, Faouzi M, Rochat I, Blanchon S.   +6 more
europepmc   +1 more source

Impact of COVID-19 and CFTR Modulators on Cystic Fibrosis: A Real-World Analysis of Care Patterns. [PDF]

Pediatr Pulmonol
Hinton AC, Sears EH, Lopez-Pintado S, Zuckerman JB.   +3 more
europepmc   +1 more source

CFTR rescue in W1282X cystic fibrosis patient-derived intestinal organoids (PDIOs) mediated by translational readthrough-inducing drugs (TRIDs). [PDF]

Genet Med Open
Perriera R, Ramalho AS, Vermeulen F, Vitale E, Pibiri I, Pace A, Lentini L.   +6 more
europepmc   +1 more source

Real-World Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis: A 24-Month Italian National Registry Study. [PDF]

J Clin Med
Salvatore D, Campagna G, Padoan R, Pepe A, Amato A, Salvatore M.   +5 more
europepmc   +1 more source

The validated French CFAbd-Score reveals a lower burden of gastrointestinal symptoms in patients on Elexacaftor/Tezacaftor/Ivacaftor. [PDF]

J Pediatr Gastroenterol Nutr
Sermet-Gaudelus I, Sadrieh P, Bonnel AS, Enaud R, Wizla N, Languepin J, Nangui A, Deelawon A, Rave J, Dabelow S, Barucha A, Zagoya C, Duckstein F, Mainz JG.   +13 more
europepmc   +1 more source

Elexacaftor/Tezacaftor/Ivacaftor in Children with Cystic Fibrosis: No Longer "If" but a Question of "When" to Start. [PDF]

Am J Respir Crit Care Med
Selvadurai H.
europepmc   +1 more source

Impact of Cystic Fibrosis Transmembrane Conductance Regulator Modulating Therapies on Liver Transplant Outcomes. [PDF]

Gastro Hep Adv
Naimimohasses S, Ray A, Tan E, Wiggins A, Hasjim BJ, Chen S, Bhat M.   +6 more
europepmc   +1 more source

Pharmacokinetic assessment of elexacaftor/tezacaftor/ivacaftor and their metabolites in maternal blood, cord blood, the neonate, and breastmilk of a cystic fibrosis carrier mother/affected fetus dyad. [PDF]

J Cyst Fibros
Sinkey RG, Garcia B, Fowler CM, Krick S, Ryan KJ, Acosta EP, Guimbellot JS.   +6 more
europepmc   +1 more source

Elexacaftor-Tezacaftor-Ivacaftor Reduces Revision Sinus Surgery in People With Cystic Fibrosis. [PDF]

Laryngoscope
Lin A, Komara M, Kistler I, Tan ZH, Lind M, Kotha K, Chiang T.   +6 more
europepmc   +1 more source